Navigation Links
Cardiologists initiate STILETTO study to investigate treatment options for women with chest pain
Date:2/24/2009

CHICAGO Women who experience chest pain are sent to a cardiologist to go through a standard battery of tests, and often times test results show no evidence of coronary artery disease which is the most common cause of chest pain. This is a less common occurrence in men, and these women are sent home with little more than reassurance but often times return to their physicians complaining of similar symptoms and are more likely to develop future cardiac events.

To better determine the cause of difficult to diagnose chest pain among women, physicians at Northwestern Memorial's Bluhm Cardiovascular Institute are initiating a research study designed to identify the prevalence of a condition called Syndrome X. This disease process affects the endothelial function of blood vessels, a condition where the layers of the cells are not functioning properly and may be undetectable by standard testing such as exercise stress test and cardiac angiography. Researchers believe that endothelial dysfunction is the earliest stage of coronary artery disease. The goal of the study is to determine a more accurate diagnosis for women who present with chest pain symptoms and to determine if a more aggressive treatment regimen than the current standard of care may be adopted in the future.

In women there may be a different disease process which could be due to endothelial dysfunction, which is not something that can be detected by the current standard of care regimen. "Given that endothelial dysfunction may be an early stage of atherosclerosis, or fat deposits in the arteries, some have suggested medical treatment and lifestyle changes similar to those recommended to women with obstructive coronary artery disease," says Martha Gulati, MD, associate medical director of the Center for Women's Cardiovascular Health and assistant professor of medicine at Northwestern University's Feinberg School of Medicine.

"There are currently no other randomized trials comparing the effectiveness of such therapy in women with cardiac symptoms, normal coronary arteries but evidence of coronary endothelial dysfunction," commented Neil Stone, MD, medical director of the Center for Vascular Disease and professor of medicine at Northwestern University's Feinberg School of Medicine.

Study participants will undergo endothelial dysfunction testing, a procedure where medication is injected into the coronary arteries to directly assess endothelial response of the arteries, in order to identify women who may be likely to develop coronary artery disease and who would benefit from aggressive lifestyle and medical interventions. These interventions include dietary counseling, exercise, and medical treatment targeting improving the endothelial dysfunction.


'/>"/>

Contact: Amy Dobrozsi
adobrozs@nmh.org
312-926-5900
Northwestern Memorial Hospital
Source:Eurekalert

Related medicine news :

1. One-Third of U.S. Primary Care Physicians and Cardiologists Do Not Currently Prescribe Treatment to Meet HDL Cholesterol Targets as Recommended By National Guidelines
2. Cardiologists Warn Proposed Changes Would Close Outpatient Cardiac Cath Labs
3. Cardiologists Spot Best Treatment for a Deadly Duo
4. Distinguished Cardiologists and Scientists Honored With 2008 International Academy of Cardiology Award
5. Dallas Cardiologists Explore Next Frontier in Vascular-Disease Treatments
6. Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C.
7. SCAIs Annual Fall Fellows Course Prepares New Interventional Cardiologists to Work in the Field
8. Res-Q Gains Rights To Market Orosine - a Breakthrough, Patented, Natural Heart Supplement That Cardiologists Are Calling the Ultimate Cardio Protection Against Heart Attacks, Strokes and Heart Failure.
9. Among Cardiologists, Women Cite Discrimination
10. Video: Cardiologists Recommend Lifestyle Habits for Healthy Hearts
11. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... California (PRWEB) , ... May 30, 2016 , ... ... easy to use inside of FCPX," said Christina Austin - CEO of Pixel ... exclusively for use within Final Cut Pro X. Choose from abstract transitions to ...
(Date:5/29/2016)... ... May 29, 2016 , ... Whole Health Supply is happy to announce ... been available via Amazon.com. This new style of nail clipper has a wider jaw ... is approximately 4mm and the actual handle is 2.5mm thick to accommodate the cutting ...
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can ... drop a preset onto their media," said Christina Austin - CEO of Pixel Film ... can quickly and easily add stylish color grades to their footage. A LUT is ...
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses and professionals in ... lights on the variety of topics detailing why we appreciate nurses in so many ... career has gone from being in a major recession to one of the hottest ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 ... biopharmaceutical company focused on late-stage drug development, today ... Pharma of pivotal batches required for registration ... Administration (FDA). This follows Kitov,s announcement ... trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... May 26, 2016 TARE ... Both Cost Savings and Overall Decreased Use ... BTG), an international specialist healthcare company, has today ... 21st Annual Meeting of ISPOR (International Society for ... hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres is ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... dringenden Bedarf zur Steuerung ... N.V. (NASDAQ: QGEN ; Frankfurt Prime ... Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung und ... sein. Ein erstes Projekt wird die Entwicklung und ...
Breaking Medicine Technology: